Wegovy Pill (oral semaglutide 25 mg)vsFoundayo (orforglipron)

Semaglutide is a GLP-1 receptor agonist. It mimics the gut hormone GLP-1 to boost glucose-dependent insulin release, slow how fast the stomach empties, and signal fullness in the brain, which together reduce appetite and calorie intake. The oral formulation uses an absorption enhancer (SNAC) to get the peptide across the stomach lining, which is why empty-stomach dosing matters.

Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist. Unlike semaglutide (a peptide that degrades in the gut and needs special absorption tricks), this small molecule is absorbed normally, so it can be taken without food or water timing rules. By activating the GLP-1 receptor it raises glucose-dependent insulin secretion, slows gastric emptying, and dampens appetite.

In the phase 3 OASIS 4 trial (NEJM, 2025; n=307 adults with overweight/obesity, without diabetes), oral semaglutide 25 mg produced an estimated mean weight change of -13.6% at week 64 versus -2.2% for placebo, with about 30% of the drug group losing at least 20% of body weight. Novo reports up to ~16.6% mean loss with full adherence, on par with injectable Wegovy 2.4 mg.

In the phase 3 ATTAIN-1 trial (NEJM, 2025; n=3,127 adults with obesity without diabetes), mean weight change at week 72 was -7.5% (6 mg), -8.4% (12 mg), and -11.2% (36 mg) versus -2.1% for placebo; Lilly also reports up to ~12.4% in adherence-based analyses. Nearly 60% on the highest dose lost at least 10% of body weight.

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation, typically worst during dose escalation and easing over time. Rare but serious risks include pancreatitis and gallbladder problems; it carries a boxed warning for thyroid C-cell tumors based on animal data. Discuss your history with a licensed provider.

Side effects are predominantly gastrointestinal (nausea, vomiting, diarrhea, constipation), mostly mild to moderate and concentrated during the titration period. As with the GLP-1 class, rare serious risks such as pancreatitis can occur. Review your medical history with a licensed provider before starting.

As of May 2026, self-pay pricing starts around $149/month for the 1.5 mg starter and 4 mg doses, with 4 mg rising to $199/month after April 15, 2026 and higher maintenance doses around $299/month. Commercially insured patients with coverage may pay as little as $25/month with the savings offer. Confirm current pricing at NovoCare or your pharmacy.

As of September 2026, LillyDirect's regular self-pay price for Foundayo is $149/month for 0.8 mg, $199 for 2.5 mg, $299 for 5.5 mg and 9 mg, and $349 for 14.5 mg and 17.2 mg; the 2.5 mg dose is temporarily reduced to $149/month through December 31, 2026. Eligible commercially insured patients may pay less with a savings card. Confirm current pricing at LillyDirect.

Intended for adults with obesity (BMI >=30) or overweight (BMI >=27) with at least one weight-related condition, used with diet and exercise. Not for people with a personal or family history of medullary thyroid carcinoma or MEN2, and prescribers screen for pancreatitis history and other GLP-1 contraindications.

For adults with obesity (BMI >=30) or overweight (BMI >=27) with at least one weight-related comorbidity, alongside diet and physical activity. Standard GLP-1 precautions apply, including screening for thyroid cancer history and pancreatitis. A prescription and clinician evaluation are required.